JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Priyanka Grover maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $28 to $31.
JP Morgan analyst Priyanka Grover maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $28 to $31.